The global vaginitis therapeutics market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising need for enhanced healthcare infrastructure, rising awareness about women's health, and the introduction of new treatments by major pharmaceutical companies.
Vaginitis refers to a range of health conditions or disorders occurred among women that are related to morbidity due to prolonged undiagnosed situation. Vaginitis is a vaginal problem that causes itchiness, pain, and discharge. The most common types of vaginitis include candida infections, tyrichomoniasis vaginitis, bacterial vaginosis, viral vaginitis, and chlamydia vaginitis. In recent years, extensive research has resulted in the development of diagnostic tools as well as treatment options for all types of vaginitis. Around one-third of the women population in the world are likely to develop vaginitis symptoms at some point. During the reproductive years in particular, women are especially vulnerable to vaginitis as a change in the balance of bacteria and yeast in the vaginal area can cause vaginitis. As per the Centers for Disease Control and Prevention (CDC) reports, more than 13 out of every 100 women are addicted to smoking cigarettes. Scientists associated with the National Institute of Allergy and Infectious Diseases (NIAID) are engaged to develop a test for yeast infection in order to give suitable antifungal treatment.
In addition, the Division of Intramural Population Health Research in NICHD, researchers are examining many aspects of the relationship between bacterial vaginosis and pregnancy outcome using both old and new data. Various government and non-government organizations, including the World Health Organization and the European Institute of Women's Health (EIWH), have launched campaigns to raise awareness about women's health.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing usage of antibiotics and growing research & development initiatives for precise diagnosis are projected to boost the market growth during the forecast period.
- Increasing women's health awareness as well as the introduction of new drugs by major pharmaceutical companies are anticipated to spur the market expansion during the forecast period.
- Rising demand for improved healthcare infrastructure and development of innovative diagnostic kits is expected to fuel the market expansion in coming years.
- Low healthcare budgets and policies in some developing countries is anticipated to impede the market growth.
- Patent expiration of branded drugs and the introduction of generic drugs are estimated to hinder the market growth.
Scope of the Report
The report on the global vaginitis therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Vaginitis Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Products (Anti-bacterial, Anti-fungal, and Hormone) and Types (Prescription and Over the counter )
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Merck & Co.; Pfizer, Inc.; Bayer AG; Novartis International AG; Symbiomix Therapeutics, Inc.; Lupin Pharmaceuticals, Inc.; and Mission Pharmacal Company.
|
Market Segment Insights
Hormone segment is expected to grow at a rapid pace
Based on products, the vaginitis therapeutics market is segregated into anti-bacterial, anti-fungal, and hormone. The anti-bacterial segment is expected to account for a key share of the market in the coming years due to rising cases of bacterial vaginosis. In terms of revenue in 2019, the anti-bacterial segment held a major market share. It was reported that approximately over 20 million women were affected by this condition. Clindamycin, metronidazole, and tinidazole are antibiotics used to treat bacterial vaginosis. However, the hormone segment is anticipated to expand at a rapid pace during the forecast period owing to the presence of strong pipeline drugs. However, most of the hormonal treatments are only available with presence of a prescription.
Over the counter segment is anticipated to register at a substantial CAGR
Based on types, the market is bifurcated into prescription and over the counter. The prescription segment is expected to constitute a key share of the market in the coming years owing to greater efficacy and safety for severe and recurring vaginitis. However, over the counter segment is anticipated to register at a substantial CAGR during the forecast period owing to the presence of a wide range of over-the-counter drugs such as gels, vaginal creams, and others. Moreover, the US Food and Drug Administration has approved therapeutic alternatives for mild vaginitis for external use for non-prescribed medications. These include pills, creams, and suppositories containing miconazole, tioconazole, butoconazole, and clotrimazole.
Asia Pacific is anticipated to dominate the market
On the basis of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Asia Pacific is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to high unmet clinical requirements, rising disposable money, and the availability of effective medications in emerging countries such as India and China. Moreover, the market expansion in the region is further accelerated due to rising awareness regarding early diagnosis and treatment availability. On the other hand, North America led the global market with a value of more than USD 850 million in 2019. The developed healthcare infrastructure, high prevalence of diseases and the presence of prominent manufacturers are the major factors for the regional market share. Other factors driving the market expansion in the region include favorable government initiatives and an expanding target population.
Segments
Segments Covered in the Report
The global vaginitis therapeutics market has been segmented on the basis of
Products
- Anti-bacterial
- Anti-fungal
- Hormone
Types
- Prescription
- Over the counter
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Merck & Co.
- Pfizer, Inc.
- Bayer AG
- Novartis International AG
- Symbiomix Therapeutics, Inc.
- Lupin Pharmaceuticals, Inc.
- Mission Pharmacal Company
Competitive Landscape
ey players competing in the global vaginitis therapeutics market include Merck & Co.; Pfizer, Inc.; Bayer AG; Novartis International AG; Symbiomix Therapeutics, Inc.; Lupin Pharmaceuticals, Inc.; and Mission Pharmacal Company.
Majority of these competitors are taking up initiatives including as collaborations, new drug development, mergers and acquisitions, and commercial expansion in emerging markets to enhance their market positions. Lupin Pharmaceuticals, for instance, acquired Symbiomix Therapeutics in October 2017 to expand its product portfolio. Pfizer Inc. announced a reconsideration of strategy in October 2017 to examine strategic alternatives for spinning off its Consumer Healthcare Business into a strategic plan.
Request For Customization
Enquiry Before Buying
Speak With Analyst
